HOME >> MEDICINE >> NEWS
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo
'"/>

Contact: Michelle Linn
linnmich@comcast.net
508-419-1555
Linnden Communications
11-Dec-2006


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
Cached News: